Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.

Blood - 1 Jun 1990

Hauch M, Gazzola M V, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O'Reilly R J, Keever C A

Abstract excerpt

The anti-leukemia potential of natural killer (NK) cells has been evaluated in 40 patients transplanted for chronic myelogenous leukemia (CML) to determine whether differences in NK cell function were correlated with subsequent leukemic relapse. Cells from patients and their donors were tested in 51Cr release assays against fully allogeneic CML targets and against cultured K562 targets; cells from 26 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Child

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Child, Preschool

Share to Fluorescent Antibody Technique

Share to Interleukin-2

Share to Killer Cells, Natural

Share to Phenotype

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 2189508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.PMID 2189508Read ↗

Improving the Outcome of Leukemia by Natural Killer Cell-Based Immunotherapeutic StrategiesSemantic proximity Read ↗

Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.Semantic proximity Read ↗

Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Determinants of Antileukemia Effects of Allogeneic NK CellsSemantic proximity Read ↗

Immunologic and clinical aspects of natural killer cells in human leukemia.Semantic proximity Read ↗

Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia.Semantic proximity Read ↗

Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients.Semantic proximity Read ↗

Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.Semantic proximity Read ↗

Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.Semantic proximity Read ↗

Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.Semantic proximity Read ↗

NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.Semantic proximity Read ↗

Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.